To aim for £1,000 a month in passive income, should I buy growth shares or value shares?

Deciding which shares are the best to invest in is important when considering long-term passive income. However, there are several factors to consider.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Passive income text with pin graph chart on business table

Image source: Getty Images

Growth shares and value shares both offer returns that can equate to a decent amount of monthly passive income. While growth shares focus on growing the business and, subsequently, the share price, value shares try attract investment through dividends.

While growth shares can be more profitable and volatile, value shares typically provide a slow yet reliable source of income.

So which is best for passive income?

Well, that depends.

It makes sense to shift focus towards dividend-paying (value) shares the closer one gets to retirement. This ensures regular payments are made throughout the year to support financial needs. But early investors who are financially stable could build a larger retirement pot from growth shares.

A portfolio of growth shares that increase at an average of 7% annually would need £171,000 invested to return £12,000 per year. Naturally, a portfolio of shares with an average 7% dividend yield would achieve similar returns. 

The trick is evaluating the growth prospects and the consistency of dividend payments to assess the best long-term option.

Evaluating a growth share

With a £237bn market cap, AstraZeneca (LSE: AZN) is one of the most popular pharmaceutical stocks on the FTSE 100. A recent earnings report revealed £47bn in revenue and £39bn in gross profit. It only has a 1.8% dividend yield but over the past 10 years, its share price has increased from £43 to £123. That equates to annualised returns of 11% per year. If it continues to grow at this rate, an investment of £10,000 would return £12,000 a year after 23 years.

But while AstraZeneca has been performing well, there is no guarantee it will continue. It faces the risk of patent expirations and strong competition from other major drug developers like Johnson & Johnson, Roche and Merck. One of AstraZeneca’s best-selling drugs, Farxiga, comes off patent in 2024. If a competitor releases a similar or better version of the drug, it could cost AstraZeneca $4.3bn in annual sales.

Evaluating a value share

By comparison, the HSBC (LSE: HSBA) share price has increased from £6.14 to £6.99 in the past 10 years – an annualised return of only 1.8%. Even though it has a high 7% dividend yield, it would take almost 30 years before it began paying out £12,000 a year. However, the dividend is expected to increase by around 0.2% per year, potentially making the stock a more profitable option in the long term.

But bank shares, while high value, pose other risks. When financial crises occur, they often bear the brunt of the losses. As it is, independent analysts estimate that HSBC’s earnings could decline at an average of 3% per year for the next three years. Reduced earnings could put pressure on the bank’s operating profits and negatively affect price performance.

The verdict

When looking to build a portfolio aiming for passive income, it’s often best to include a mix of growth and value shares. This is particularly important when looking at a long timeline of 30+ years. In this way, the portfolio could benefit from growth shares during strong economic periods and remain stable from value shares during tough times.

However, as retirement draws near, it may be beneficial to weight the portfolio more towards value shares. This should help to ensure a more stable and regular income from dividend payments.

HSBC Holdings is an advertising partner of The Ascent, a Motley Fool company. Mark Hartley has positions in AstraZeneca Plc and HSBC Holdings. The Motley Fool UK has recommended AstraZeneca Plc and HSBC Holdings. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Businessman hand stacking up arrow on wooden block cubes
Growth Shares

Why I think the HSBC share price could hit 2,000p by December

Jon Smith explains why the HSBC share price could be primed to rally for the rest of the year, despite…

Read more »

Elevated view over city of London skyline
Investing Articles

£15,000 invested in UK shares a decade ago is now worth…

How have UK shares performed in recent years? That depends which ones you have in mind, as our writer explains.…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

3 FTSE shares with many years of consecutive dividend growth

Paul Summers picks out a selection of FTSE shares that have offered passive income seekers consistency for quite a long…

Read more »

piggy bank, searching with binoculars
Investing Articles

Prediction: Diageo shares could soar in the next 5 years if this happens…

Diageo shares have been in the doldrums for some years now. What on earth could waken this FTSE 100 dud…

Read more »

Investing Articles

With a P/E of 5.9 is this a once-in-a-decade opportunity to buy dirt-cheap easyJet shares?

Today marks a fresh low for easyJet shares, which are falling on a disappointing set of first-half results. Harvey Jones…

Read more »

Investing Articles

Think the soaring Tesco share price is too good to be true? Read this…

The Tesco share price keeps climbing. It's up again today, following a positive set of results, but Harvey Jones says…

Read more »

Artillery rocket system aimed to the sky and soldiers at sunset.
Investing Articles

BAE Systems shares are up 274% in 46 months. And I reckon there could be more to come

Our writer’s been learning about the state of Britain’s defence forces. And he thinks it could be good news for…

Read more »

Stack of British pound coins falling on list of share prices
Investing Articles

5 years ago, £5,000 bought 218 Greggs shares. How many would it buy now?

Greggs sells around 150m sausage rolls every year. But have those who bought the baker’s shares in April 2021 made…

Read more »